BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Par Pharmaceutical, Inc. Begins Shipment of Rizatriptan Benzoate Tablets and Rizatriptan Benzoate Orally Disintegrating Tablets


1/3/2013 8:27:43 AM

WOODCLIFF LAKE, N.J., Jan. 2, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating subsidiary has begun shipping 5 mg and 10 mg strengths of rizatriptan benzoate tablets and 5 mg and 10 mg strengths of rizatriptan benzoate orally disintegrating tablets. Rizatriptan benzoate tablets and rizatriptan benzoate orally disintegrating tablets are each indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years of age. According to IMS Health data, annual U.S. sales of rizatriptan benzoate total approximately $653 million.

Important Information About Rizatriptan Benzoate Tablets and Rizatriptan Benzoate Orally Disintegrating Tablets
Rizatriptan benzoate is contraindicated in patients with ischemic artery disease or other significant underlying cardiovascular disease, coronary artery vasospasm including Prinzmetal's angina, history of stroke or transient ischemic attack (TIA), peripheral vascular disease (PVD), ischemic bowel disease, uncontrolled hypertension, recent use of another 5-HT1 agonist, ergotamine-containing medication, or ergot-type medication, hemiplegic or basilar migraine, concurrent administration or recent discontinuation of a MAO-A inhibitor and hypersensitivity to rizatriptan benzoate tablets or rizatriptan benzoate orally disintegrating tablets.

About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals. For press release and other company information, visit www.parpharm.com.

SOURCE Par Pharmaceutical Companies, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES